Page 85 - AN-3-3

Advanced Neurology mTOR inhibition in epilepsy

98. Zhang B, McDaniel SS, Rensing NR, Wong M. Vigabatrin doi: 10.1111/bcp.13780
inhibits seizures and mTOR pathway activation in a
mouse model of tuberous sclerosis complex. PLoS One. 106. Amin S, Mallick AA, Edwards H, et al. The metformin in
tuberous sclerosis (MiTS) study: A randomised double-blind
2013;8(2):e57445.
placebo-controlled trial. EClinicalMedicine. 2021;32:100715.
doi: 10.1371/journal.pone.0057445
doi: 10.1016/j.eclinm.2020.100715
99. Bombardieri R, Pinci M, Moavero R, Cerminara C,
Curatolo P. Early control of seizures improves long-term 107. Kotulska K, Chmielewski D, Borkowska J, et al. Long-term
outcome in children with tuberous sclerosis complex. Eur J effect of everolimus on epilepsy and growth in children
Paediatr Neurol. 2010;14(2):146-149. under 3 years of age treated for subependymal giant cell
astrocytoma associated with tuberous sclerosis complex. Eur
doi: 10.1016/j.ejpn.2009.03.003 J Paediatr Neurol. 2013;17(5):479-485.
100. Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. doi: 10.1016/j.ejpn.2013.03.002
Antiepileptic treatment before the onset of seizures reduces
epilepsy severity and risk of mental retardation in infants 108. Wiegand G, May TW, Ostertag P, Boor R, Stephani U,
with tuberous sclerosis complex. Eur J Paediatr Neurol. Franz DN. Everolimus in tuberous sclerosis patients with
2011;15(5):424-431. intractable epilepsy: A treatment option? Eur J Paediatr
Neurol. 2013;17(6):631-638.
doi: 10.1016/j.ejpn.2011.03.010
doi: 10.1016/j.ejpn.2013.06.002
101. Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention
of epilepsy in infants with tuberous sclerosis complex 109. Krueger DA, Wilfong AA, Mays M, et al. Long-term
in the EPISTOP trial. Ann Neurol. 2021;89(2):304-314. treatment of epilepsy with everolimus in tuberous sclerosis.
doi: 10.1002/ana.25956 Neurology. 2016;87(23):2408-2415.
102. Bebin EM, Peters JM, Porter BE, et al. Early treatment with doi: 10.1212/WNL.0000000000003400
vigabatrin does not decrease focal seizures or improve 110. Samueli S, Abraham K, Dressler A, et al. Efficacy and safety
cognition in tuberous sclerosis complex: The PREVeNT of Everolimus in children with TSC-associated epilepsy-
trial. Ann Neurol. 2023;95:15-26. pilot data from an open single-center prospective study.
doi: 10.1002/ana.26778 Orphanet J Rare Dis. 2016;11(1):145.
103. Krueger D. Stopping TSC Onset and Progression 2B: Sirolimus doi: 10.1186/s13023-016-0530-z
TSC Epilepsy Prevention Study (TSC-STEPS); 2023. Available 111. Mizuguchi M, Ikeda H, Kagitani-Shimono K, et al.
from: https://clinicaltrials.gov/study/NCT05104983 [Last Everolimus for epilepsy and autism spectrum disorder in
accessed on 2024 Apr 29].
tuberous sclerosis complex: EXIST-3 substudy in Japan.
104. Kotulska K. Efficacy and Safety of Rapamycin Versus Brain Dev. 2019;41(1):1-10.
Vigabatrin in the Prevention of Tuberous Sclerosis Complex doi: 10.1016/j.braindev.2018.07.003
Symptoms in Infants (ViRap); 2024. Available from: https://
clinicaltrials.gov/study/NCT04987463 [Last accessed on 112. Stockinger J, Strzelczyk A, Nemecek A, et al. Everolimus
2024 May 29]. in adult tuberous sclerosis complex patients with epilepsy:
Too late for success? A retrospective study. Epilepsia.
105. Amin S, Lux A, O’Callaghan F. The journey of metformin from
glycaemic control to mTOR inhibition and the suppression 2021;62(3):785-794.
of tumour growth. Br J Clin Pharmacol. 2019;85(1):37-46. doi: 10.1111/epi.16829

Volume 3 Issue 3 (2024) 21 doi: 10.36922/an.3568